SYK STRYKER CORPORATION

Stryker completes acquisition of K2M

Stryker completes acquisition of K2M

Kalamazoo, Michigan, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) has completed the previously announced acquisition of K2M Group Holdings, Inc., a global leader of complex spine and minimally invasive solutions.

"K2M's broad product portfolio and robust pipeline complement Stryker’s leadership in the spine and neurotechnology markets," said Spencer S. Stiles, Group President, Neurotechnology, Instruments and Spine. "We believe that our combined businesses will offer innovative solutions for our customers while expanding our global footprint.”

Forward-looking statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unexpected charges or expenses in connection with the acquisition of K2M; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II recall matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions, including the acquisition of K2M; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at .

Contacts

For investor inquiries please contact:

Katherine A. Owen, Stryker, 269-385-2600 or

For media inquiries please contact:

Yin Becker, Stryker, 269-385-2600 or

EN
09/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STRYKER CORPORATION

Stryker Corp: 1 director

A director at Stryker Corp sold 500,000 shares at 363.439USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

Stryker declares an $0.88 per share quarterly dividend

Stryker declares an $0.88 per share quarterly dividend Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services i...

 PRESS RELEASE

Stryker reports 2025 operating results and 2026 outlook

Stryker reports 2025 operating results and 2026 outlook Portage, Michigan, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2025: Fourth Quarter Results Reported net sales increased 11.4% to $7.2 billionOrganic net sales increased 11.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 100 bps to 30.2%Reported EPS increased 56.0% to $2.20Adjusted EPS(1) increased 11.5% to $4.47  Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitio...

 PRESS RELEASE

Stryker to announce financial results for its fourth quarter and full ...

Stryker to announce financial results for its fourth quarter and full year 2025 Portage, Michigan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2025 on Thursday, January 29, 2026.  A press release will be issued at approximately 4:05 p.m. ET and available at that day. The press release will include summary financial information for the company’s fourth quarter and full year that ended December 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, January 29, 2026, to discuss its fo...

 PRESS RELEASE

Stryker declares an $0.88 per share quarterly dividend

Stryker declares an $0.88 per share quarterly dividend Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter.  “We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share,” said Kevin Lobo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch